Cannabis sativa active compounds are extensively studied for their therapeutic effects, beyond the well-known psychotropic activity. C. Sativa is used to treat different medical indications, such as multiple sclerosis, spasticity, epilepsy, ulcerative colitis and pain. Simultaneously, basic research is discovering new constituents of cannabis-derived compounds and their receptors capable of neuroprotection and neuronal activity modulation. The function of the various phytochemicals in different therapeutic processes is not fully understood, but their significant role is starting to emerge and be appreciated. In this review, we will consider the structure-activity relationship (SAR) of cannabinoid compounds able to bind to cannabinoid receptors and act as therapeutic agents in neuronal diseases, e.g., Parkinson’s disease. © 2018 by the authors.

Structure-activity relationship of cannabis derived compounds for the treatment of neuronal activity-related diseases

Prandi, Cristina;Blangetti, Marco;KOLTAI, HINANIT HANA RIVKA
2018-01-01

Abstract

Cannabis sativa active compounds are extensively studied for their therapeutic effects, beyond the well-known psychotropic activity. C. Sativa is used to treat different medical indications, such as multiple sclerosis, spasticity, epilepsy, ulcerative colitis and pain. Simultaneously, basic research is discovering new constituents of cannabis-derived compounds and their receptors capable of neuroprotection and neuronal activity modulation. The function of the various phytochemicals in different therapeutic processes is not fully understood, but their significant role is starting to emerge and be appreciated. In this review, we will consider the structure-activity relationship (SAR) of cannabinoid compounds able to bind to cannabinoid receptors and act as therapeutic agents in neuronal diseases, e.g., Parkinson’s disease. © 2018 by the authors.
2018
23
7
1526
1543
http://www.mdpi.com/1420-3049/23/7/1526/pdf
Cannabinoid receptors; Cannabis sativa; Endocannabinoids; Neuronal diseases; Parkinson’s disease; Phytocannabinoids; Structure-activity relationship; Cannabis; Endocannabinoids; Humans; Phytochemicals; Receptors, Cannabinoid; Structure-Activity Relationship; Analytical Chemistry; Chemistry (miscellaneous); Molecular Medicine; 3003; Drug Discovery3003 Pharmaceutical Science; Physical and Theoretical Chemistry; Organic Chemistry
Prandi, Cristina; Blangetti, Marco; Namdar, Dvora; Koltai, Hinanit*
File in questo prodotto:
File Dimensione Formato  
molecules-23-01526.pdf

Accesso aperto

Descrizione: articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 3.8 MB
Formato Adobe PDF
3.8 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1685154
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact